Role of Interleukin 23 in Systemic Lupus Erythematosus Related Interstial Lung Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- interleukin 23
研究概览
简要总结
assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .
详细描述
for all patients detailed history taken clinical and rhumatological examination will be assessed and SLEDAI score will be collected from the case record of the patients&laboratory investigation included 1_erythrocytic sedimentation rate.2_complete blood count.3_interleukin23 .4_complement 3&4.5_Antinuclear Antibodies.6_Anti double stranded antibodies.7_full basic biochemical test(24 urine protien)8_high resolution computed tomography.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.
排除标准
- •patients with chest conditions rather than interstial lung disease &who receiving biological blocking antibodies& those treated with immunosuppressive drugs.
研究组 & 干预措施
group 1
Patients with systemic lupus erythematosus without interstial lung disease.
干预措施: interleukin 23 (Biological)
group2
Patients with systemic lupus erythematosus with interstial lung disease.
干预措施: interleukin 23 (Biological)
group3
healthy control groups
干预措施: interleukin 23 (Biological)
结局指标
主要结局
interleukin 23
时间窗: 2 years
level of interleukin 23 in Sera of patients with systemic lupus erythematosus using ELIZA
次要结局
未报告次要终点
研究者
khadiga Mahmoud Salem
resident doctor at clinical pathology department
Sohag University